AR066266A1 - DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR - Google Patents
DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLORInfo
- Publication number
- AR066266A1 AR066266A1 ARP080101710A ARP080101710A AR066266A1 AR 066266 A1 AR066266 A1 AR 066266A1 AR P080101710 A ARP080101710 A AR P080101710A AR P080101710 A ARP080101710 A AR P080101710A AR 066266 A1 AR066266 A1 AR 066266A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- 6alkoxy
- acid
- 6haloalkyl
- phenyl
- Prior art date
Links
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 title 1
- -1 cyano, hydroxy Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000005494 pyridonyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composicion farmacéutica que contiene dichos compuestos y uso de dichos compuestos en la terapia. La presente se relaciona además con el proceso para la preparacion de dichos compuestos y con los nuevos productos intermedios utiles en la preparacionde los mismos Reivindicacion 1: Un compuesto de formula 1, donde: X es O o CH2; R1 es piridinil, pirazolil, isoxazolil, pirimidinil, piridazinil, imidazopiridinil o pirazinil, el cual puede ser independientemente mono-, bi-o tri-sustituido con R11,R12, y/o R13; donde R11, R12 y R13 son independientemente seleccionados de halogeno, C1-6alquil, C1-6alcoxi, C3-6cicloalquil, C 1-6hidroxialquil, C3-6cicloalquiloxi, C3-6cicloaIquil C1-6alcoxi, ciano, hidroxi, C1-6 haloalquil, C 1-6haloalcoxi, C1-6haloalcoxi C1-6alcoxi, C1-6haloalcoxi C1-6alquil, ácido C1-6alquilsulfonico-, ácido C1-6haloalquilsulfonico-, ácido C3-6cicloalquilsulfonico-, ácido C3-6halocicloalquilsulfonico-, ácido C3-6cicloalquil C1-6alquilsulfonico-, ácido C3-6halocicloalquil C 1-6alquilsulfonico-, C1-6alquilsulfoniI-, C1-6haloalquilsulfonil-, C3-6cicloalquilsulfoniI-, C3-6halocicloalquilsulfoniI-, C3-6cicloalquil C1-6alquilsulfonil, C3-6halocicloalquil C1-6alquil-sulfonil, fenil, fenilC1-6alquil-,fenoxi, C1-6aquilfenil-, C1-6alcoxifenil-, C1-6alquilamina, C1-6haloalquilamina, -C(O)NHC1-6alquil, -C(O)N(C1-6alquil)2 y -C(O)NH2; R2 es pirazinil, fenil, piridinil, quinoxalinil, triazolil, piridonil, naftiridinil, pirimidinil o quinolinil, elcual puede ser independientemente mono-, bi-, o tri-sustituido con R14, R15 y/o R16; donde R14, R15 y R16 son independientemente seleccionados de halogeno, C1-6alquil, C2-6alquenil, C3-6alquinil, C1-6alcoxi, C2-6alqueniloxi, C3-6alquiniloxi, C3-6cicloalquil, C3-6heterocicloalquil, C3-6cicloalquiloxi, C3-6heterocicIoalquiloxi, C3-6cicloalquil C1-6alcoxi, C1-6alquil-C3-6cicloalquil C1-6alcoxi, C3-6heterocicloalquil C1-6alcoxi, C1-6alquil-C3-6heterocicloaIquil C1-6alcoxi, C1-6alcoxi C1-6alcoxi, C1-6alcoxi C1-6alquil, C1-6hidroxialquil, C1-6haloalquil, C1-6haloalcoxi, C1-6haloalcoxi C1-6alcoxi, C1-6haloalcoxi C1-6alquil, ciano, hidroxil, NR4R5, ácido C1-6alquilsulfonico-, ácido C1-6haloalquilsulfonico-, ácido C3-6cicloalquilsulfonico-, ácido C3-6halocicloalquilsulfonico-, ácido C3-6cicIoalquil C1-6alquilsulfonico-, ácido C3-6halocicloalquil C1-6alquilsulfonico-, C1-6alquilsulfonil-, C1-6haloalquilsulfonil-, C3-6cicloalquilsulfonil-, C3-6halocicloalquilsulfonil-, C3-6cicloalquil- C1-6alquil-sulfonil, C3-6halocicloalquil-C1-6alquil-sulfonil, fenil, fenilC1-6alquil-, fenoxi, C1-6alquilfenil-, C1-6alcoxifenil-, -C(O)NR4R5, -C(O)C3-6cicloalquil, -C(O)C3-6heterocicloalquil, -C(O)C3-6cicloalquilC1-6alcoxi, -C(O)C3-6heterocicloalquilC1-6:alcoxi, -C(O)C3-6cicloalquilC1-6alquil y -C(O)C3-6heterocicloalquilC1-6alquiI; y R4 y R5 son independientemente seleccionados de hidrogeno, C1-6alquil, C1-6haloalquil, C1-6hidroxialquil, C1-6alcoxiC1-6alquil, C3-6cicloalquil, C3-6halocicloalquil, C3-6heterocicloalquil y C3-6heterocicloalquilC1-6alquil, o sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91331207P | 2007-04-23 | 2007-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066266A1 true AR066266A1 (es) | 2009-08-05 |
Family
ID=39876087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101710A AR066266A1 (es) | 2007-04-23 | 2008-04-23 | DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8143408B2 (es) |
| EP (1) | EP2158198B1 (es) |
| JP (1) | JP2010525056A (es) |
| KR (1) | KR20100015827A (es) |
| CN (1) | CN101687860B (es) |
| AR (1) | AR066266A1 (es) |
| AU (1) | AU2008241610B2 (es) |
| BR (1) | BRPI0810354A2 (es) |
| CA (1) | CA2685141A1 (es) |
| CL (1) | CL2008001170A1 (es) |
| CO (1) | CO6251361A2 (es) |
| EC (1) | ECSP099706A (es) |
| IL (1) | IL201309A0 (es) |
| MX (1) | MX2009011364A (es) |
| MY (1) | MY146662A (es) |
| NZ (1) | NZ581353A (es) |
| PE (1) | PE20090727A1 (es) |
| RU (1) | RU2460730C2 (es) |
| SA (1) | SA08290245B1 (es) |
| TW (1) | TW200848037A (es) |
| UY (1) | UY31046A1 (es) |
| WO (1) | WO2008130320A2 (es) |
| ZA (1) | ZA200907137B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| AR074760A1 (es) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| US8748623B2 (en) * | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
| KR20120091240A (ko) * | 2009-10-26 | 2012-08-17 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물의 합성 및 정제 방법 |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| EP2532656A1 (en) | 2010-02-01 | 2012-12-12 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| JP6486002B2 (ja) * | 2010-08-23 | 2019-03-20 | シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
| WO2012039657A1 (en) * | 2010-09-22 | 2012-03-29 | Astrazeneca Ab | Novel chromane compound for the treatment of pain disorders |
| CN102408385B (zh) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102408386B (zh) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102603659B (zh) * | 2012-03-01 | 2014-03-26 | 雅本化学股份有限公司 | 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法 |
| KR102226587B1 (ko) * | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| SG11201606367YA (en) * | 2014-02-06 | 2016-09-29 | Abbvie Inc | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
| KR102245930B1 (ko) | 2015-11-13 | 2021-04-29 | 주식회사 대웅제약 | 소디움 채널 차단제 |
| CN105541774B (zh) * | 2016-01-13 | 2018-06-15 | 华中师范大学 | 3,4-二氢香豆素类化合物及其制备方法和用途 |
| PE20200608A1 (es) * | 2017-06-30 | 2020-03-10 | Bayer Animal Health Gmbh | Nuevos derivados de azaquinolina |
| EP3740481B9 (en) | 2018-01-19 | 2024-10-23 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| CA3093189A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| WO2020005888A1 (en) | 2018-06-26 | 2020-01-02 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| PL3851436T3 (pl) | 2018-09-10 | 2024-12-16 | Kaken Pharmaceutical Co., Ltd. | Nowa heteroaromatyczna pochodna amidowa i lek ją zawierający |
| WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| CA3209557A1 (en) | 2021-03-04 | 2022-09-09 | Bradley P. Morgan | Cardiac sarcomere inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904361D0 (sv) * | 1989-12-22 | 1989-12-22 | Astra Ab | New chroman and thiochroman derivatives |
| WO1994012493A1 (en) * | 1992-11-25 | 1994-06-09 | Sandoz, Ltd. | 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals |
| JPH0827153A (ja) * | 1994-07-12 | 1996-01-30 | Nippon Kayaku Co Ltd | アザクロマン誘導体及びその用途 |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| GB9713804D0 (en) * | 1997-06-30 | 1997-09-03 | Novo Nordisk As | Particulate polymeric materials and their use |
| JPH1135569A (ja) | 1997-07-22 | 1999-02-09 | Meiji Milk Prod Co Ltd | ポリフェノール化合物及びこれを含有する医薬 |
| SE9702799D0 (sv) * | 1997-07-25 | 1997-07-25 | Astra Ab | New compounds |
| SE9703378D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| SE9703377D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| WO2005013914A2 (en) * | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| US7858786B2 (en) * | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
| WO2008008020A1 (en) * | 2006-07-12 | 2008-01-17 | Astrazeneca Ab | 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents |
| SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
-
2008
- 2008-04-21 SA SA8290245A patent/SA08290245B1/ar unknown
- 2008-04-22 BR BRPI0810354-2A2A patent/BRPI0810354A2/pt not_active IP Right Cessation
- 2008-04-22 JP JP2010506133A patent/JP2010525056A/ja active Pending
- 2008-04-22 WO PCT/SE2008/050459 patent/WO2008130320A2/en not_active Ceased
- 2008-04-22 CA CA002685141A patent/CA2685141A1/en not_active Abandoned
- 2008-04-22 NZ NZ581353A patent/NZ581353A/en not_active IP Right Cessation
- 2008-04-22 KR KR1020097022164A patent/KR20100015827A/ko not_active Withdrawn
- 2008-04-22 MY MYPI20094419A patent/MY146662A/en unknown
- 2008-04-22 RU RU2009138137/04A patent/RU2460730C2/ru not_active IP Right Cessation
- 2008-04-22 MX MX2009011364A patent/MX2009011364A/es active IP Right Grant
- 2008-04-22 EP EP08779260A patent/EP2158198B1/en active Active
- 2008-04-22 US US12/596,878 patent/US8143408B2/en not_active Expired - Fee Related
- 2008-04-22 CN CN2008800215491A patent/CN101687860B/zh not_active Expired - Fee Related
- 2008-04-22 AU AU2008241610A patent/AU2008241610B2/en not_active Ceased
- 2008-04-23 UY UY31046A patent/UY31046A1/es not_active Application Discontinuation
- 2008-04-23 CL CL2008001170A patent/CL2008001170A1/es unknown
- 2008-04-23 TW TW097114910A patent/TW200848037A/zh unknown
- 2008-04-23 PE PE2008000697A patent/PE20090727A1/es not_active Application Discontinuation
- 2008-04-23 AR ARP080101710A patent/AR066266A1/es not_active Application Discontinuation
-
2009
- 2009-10-01 IL IL201309A patent/IL201309A0/en unknown
- 2009-10-13 ZA ZA200907137A patent/ZA200907137B/xx unknown
- 2009-10-29 CO CO09122476A patent/CO6251361A2/es not_active Application Discontinuation
- 2009-10-29 EC EC2009009706A patent/ECSP099706A/es unknown
-
2012
- 2012-03-23 US US13/427,981 patent/US20120238579A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008241610B2 (en) | 2011-08-18 |
| RU2460730C2 (ru) | 2012-09-10 |
| WO2008130320A3 (en) | 2008-12-18 |
| NZ581353A (en) | 2012-02-24 |
| KR20100015827A (ko) | 2010-02-12 |
| PE20090727A1 (es) | 2009-07-23 |
| US20120238579A1 (en) | 2012-09-20 |
| EP2158198B1 (en) | 2013-03-20 |
| US20100137322A1 (en) | 2010-06-03 |
| CA2685141A1 (en) | 2008-10-30 |
| CO6251361A2 (es) | 2011-02-21 |
| UY31046A1 (es) | 2008-11-28 |
| IL201309A0 (en) | 2010-05-31 |
| EP2158198A2 (en) | 2010-03-03 |
| CN101687860B (zh) | 2012-07-04 |
| US8143408B2 (en) | 2012-03-27 |
| WO2008130320A2 (en) | 2008-10-30 |
| EP2158198A4 (en) | 2012-01-04 |
| JP2010525056A (ja) | 2010-07-22 |
| RU2009138137A (ru) | 2011-05-27 |
| MY146662A (en) | 2012-09-14 |
| AU2008241610A1 (en) | 2008-10-30 |
| TW200848037A (en) | 2008-12-16 |
| SA08290245B1 (ar) | 2012-02-12 |
| MX2009011364A (es) | 2009-11-05 |
| ECSP099706A (es) | 2009-11-30 |
| BRPI0810354A2 (pt) | 2014-10-21 |
| ZA200907137B (en) | 2010-07-28 |
| CL2008001170A1 (es) | 2009-05-22 |
| CN101687860A (zh) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066266A1 (es) | DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR | |
| ES2645638T3 (es) | Derivados de 5-fenoxi-3H-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del VIH | |
| ES2683445T3 (es) | Benzamidas sustituidas para el tratamiento de artrópodos | |
| ES2438240T3 (es) | Nuevos derivados de biaril benzoimidazol y composición farmacéutica que los comprenden | |
| JP5244095B2 (ja) | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| AR064505A1 (es) | Derivados ester o amida de imidazolilo, composiciones farmaceuticas que los comprenden,proceso de preparacion, y usos como medicamentos para el tratamiento de enfermedades inflamatorias, entre otras. | |
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| AR041467A1 (es) | Indol-3-carboxamidas como activadores de glucoquinasa (gk) | |
| PE20081806A1 (es) | Imidazo- y triazolopirimidinas sustituidas | |
| CA2634676A1 (en) | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp | |
| RU2015134558A (ru) | Моноциклическое пиридиновое производное | |
| WO2017106226A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| JP2019536766A (ja) | ２−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途 | |
| ES2588835T3 (es) | Compuestos de pirazol como inhibidores de SGLT1 | |
| CN102858177A (zh) | 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途 | |
| JP2023002688A (ja) | ＮｏｔｃｈシグナリングのエンハンサーならびにＮｏｔｃｈのアップレギュレーションにより治療可能ながんおよび悪性腫瘍の治療におけるその使用 | |
| JP2016501869A (ja) | α−（３，５−ジメトキシベンジリデン）−α’−炭化水素基メチレン環状ケトン | |
| JP7681599B2 (ja) | 選択的ｃｄｋ４／６阻害剤のがん治療薬 | |
| AU2018215089C1 (en) | Anti-fibrotic compounds | |
| JP5319457B2 (ja) | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 | |
| CN103006449A (zh) | 酪氨酸酶抑制剂及其制备方法 | |
| WO2019105234A1 (zh) | 芳香族化合物及其药物组合物和用途 | |
| JP2018536652A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |